GHRP-6
Growth Hormone Releasing Peptide-6, Growth hormone-releasing hexapeptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2
Novel orally active growth hormone secretagogues.
Hansen. T K TK; Ankersen. M M; Hansen. B S BS; Raun. K K; Nielsen. K K KK; Lau. J J; Peschke. B B; Lundt. B F BF; Thøgersen. H H; Johansen. N L NL; Madsen. K K; Andersen. P H PH
Key Findings
- A novel series of growth‑hormone‑releasing compounds (500‑650 Da) was designed by shrinking the known peptide ipamorelin and reducing hydrogen‑bonding.
- Oral bioavailability in dogs ranged from 10 % to 55 %, indicating that the molecules can survive the gut and enter the bloodstream.
- In vivo potency was confirmed in swine; the best compound had an ED50 of ~30 nmol/kg after intravenous dosing.
Practical Outcomes
- These results suggest that oral growth‑hormone secretagogues could eventually replace injections, but the data are still limited to animal models. Biohackers should view this as a promising direction rather than a ready‑to‑use protocol, and wait for human safety and dosing studies before considering any self‑experimentation.
Summary
Scientists have created a new, smaller class of compounds that can trigger the body to release growth hormone and can be taken by mouth. In animal tests (pigs and dogs) these molecules showed decent oral absorption (10‑55%) and kept their ability to boost growth hormone, with the most potent one working at a dose of about 30 nmol per kilogram of body weight.
Abstract
A novel class of growth hormone-releasing compounds with a molecular weight in the range from 500 to 650 has been discovered. The aim of this study was to obtain growth hormone secretagogues with oral bioavailability. By a rational approach we were able to reduce the size of the lead compound ipamorelin (4) and simultaneously to reduce hydrogen-bonding potential by incorporation of backbone isosters while retaining in vivo potency in swine. A rat pituitary assay was used for screening of all compounds and to evaluate which compounds should be tested further for in vivo potency in swine and oral bioavailability, fpo, in dogs. Most of the tested compounds had fpo in the range of 10-55%. In vivo potency in swine after iv dosing is reported, and ED50 was found to be 30 nmol/kg of body weight for the most potent compound.
Study Information
pubmed
1998
1998-09-10T00:00:00.000Z
10.1021/jm980197u